KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Current Assets: 2010-2024

Historic Current Assets for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $598.7 million.

  • Emergent BioSolutions' Current Assets rose 18.97% to $786.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $786.9 million, marking a year-over-year increase of 18.97%. This contributed to the annual value of $598.7 million for FY2024, which is 11.89% down from last year.
  • Emergent BioSolutions' Current Assets amounted to $598.7 million in FY2024, which was down 11.89% from $679.5 million recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Current Assets registered a high of $1.3 billion during FY2021, and its lowest value of $598.7 million during FY2024.
  • Over the past 3 years, Emergent BioSolutions' median Current Assets value was $679.5 million (recorded in 2023), while the average stood at $829.5 million.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 74.28% in 2020, then plummeted by 43.86% in 2023.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Current Assets stood at $1.2 billion in 2020, then rose by 6.19% to $1.3 billion in 2021, then declined by 4.69% to $1.2 billion in 2022, then tumbled by 43.86% to $679.5 million in 2023, then declined by 11.89% to $598.7 million in 2024.